MDTH Medcath Corp. (MM)

 

 

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 10-Q

(Mark One)

þ		QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.

For the quarterly period ended June 30, 2009

Or

o		TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Commission File Number 000-33009

MEDCATH CORPORATION

(Exact name of registrant as specified in its charter)

Delaware (State or other jurisdiction of		56-2248952 (IRS Employer Identification No.)
incorporation or organization)

10720 Sikes Place, Suite 300
Charlotte, North Carolina 28277
(Address of principal executive offices, including zip code)

(704) 815-7700
(Registrant’s telephone number, including area code)

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes þ       No o

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

Yes o       No o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer o		Accelerated filer þ		Non-accelerated filer o		Smaller reporting company o
				(Do not check if a smaller reporting company)

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes o       No þ

As of August 4, 2009, there were 19,641,519 shares of $0.01 par value common stock outstanding.

 

 

MEDCATH CORPORATION
FORM 10-Q
TABLE OF CONTENTS

		Page
PART I. FINANCIAL INFORMATION			1
Item 1. Unaudited Financial Statements			1
Consolidated Balance Sheets as of June 30, 2009 and September 30, 2008			1
Consolidated Statements of Income for the Three and Nine Months Ended June 30, 2009 and 2008			2
Consolidated Statement of Stockholders’ Equity for the Nine Months Ended June 30, 2009			3
Consolidated Statements of Cash Flows for the Nine Months Ended June 30, 2009 and 2008			4
Notes to Unaudited Consolidated Financial Statements			5
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations			15
Item 3. Quantitative and Qualitative Disclosures About Market Risk			24
Item 4. Controls and Procedures			24
PART II. OTHER INFORMATION			24
Item 1. Legal Proceedings			24
Item 1A. Risk Factors			24
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds			25
Item 6. Exhibits			25
SIGNATURES			26
EX-31.1
EX-31.2
EX-32.1
EX-32.2

PART I. FINANCIAL INFORMATION

Item 1. Unaudited Financial Statements

MEDCATH CORPORATION

CONSOLIDATED BALANCE SHEETS

(In thousands, except per share data)

(Unaudited)

		June 30,				September 30,
		2009				2008
Current assets:
Cash and cash equivalents		$	42,857			$	93,836
Restricted cash			3,166				3,154
Accounts receivable, net			76,205				83,875
Income tax receivable			3,940				3,091
Medical supplies			18,335				15,479
Deferred income tax assets			7,600				9,769
Prepaid expenses and other current assets			12,235				9,796
Current assets of discontinued operations			10,052				20,776
Total current assets			174,390				239,776
Property and equipment, net			370,418				323,729
Investments in affiliates			13,261				15,285
Goodwill			60,174				60,174
Other intangible assets, net			5,974				6,063
Other assets			13,167				8,378
Long-term assets of discontinued operations			—				51
Total assets		$	637,384			$	653,456
Current liabilities:
Accounts payable		$	40,613			$	41,642
Accrued compensation and benefits			17,980				16,872
Other accrued liabilities			25,793				24,054
Current portion of long-term debt and obligations under capital leases			19,133				31,920
Current liabilities of discontinued operations			9,560				10,184
Total current liabilities			113,079				124,672
Long-term debt			104,683				115,628
Obligations under capital leases			4,111				2,087
Deferred income tax liabilities			12,267				12,352
Other long-term obligations			6,882				4,454
Total liabilities			241,022				259,193
Commitments and contingencies
Minority interest in equity of consolidated subsidiaries			18,737				24,667
Stockholders’ equity:
Preferred stock, $0.01 par value, 10,000,000 shares authorized; none issued			—				—
Common stock, $0.01 par value, 50,000,000 shares authorized; 21,691,780 issued and 19,737,419 outstanding at June 30, 2009 21,553,054 issued and 19,598,693 outstanding at September 30, 2008			216				216
Paid-in capital			455,346				455,494
Accumulated deficit			(32,814	)			(41,138	)
Accumulated other comprehensive loss			(326	)			(179	)
Treasury stock, at cost; 1,954,361 shares at June 30, 2009 1,954,361 shares at September 30, 2008			(44,797	)			(44,797	)
Total stockholders’ equity			377,625				369,596
Total liabilities and stockholders’ equity		$	637,384			$	653,456

See notes to unaudited consolidated financial statements.

MEDCATH CORPORATION

CONSOLIDATED STATEMENTS OF INCOME

(In thousands, except per share data)

(Unaudited)

		Three Months Ended June 30,								Nine Months Ended June 30,
		2009				2008				2009				2008
Net revenue		$	150,904			$	154,273			$	462,874			$	455,168
Operating expenses:
Personnel expense			50,862				50,520				153,644				150,060
Medical supplies expense			44,995				42,757				131,457				123,155
Bad debt expense			12,547				10,235				34,558				31,852
Other operating expenses			31,441				29,555				96,022				88,996
Pre-opening expenses			754				149				1,340				643
Depreciation			7,858				7,505				23,258				22,535
Amortization			230				149				589				411
(Gain) loss on disposal of property, equipment and other assets			(26	)			225				138				391
Total operating expenses			148,661				141,095				441,006				418,043
Income from operations			2,243				13,178				21,868				37,125
Other income (expenses):
Interest expense			(1,151	)			(3,862	)			(5,339	)			(11,658	)
Loss on early extinguishment of debt			—				—				(6,702	)			—
Interest and other income			52				284				218				1,930
Equity in net earnings of unconsolidated affiliates			2,265				2,636				7,044				6,842
Total other income (expense), net			1,166				(942	)			(4,779	)			(2,886	)
Income from continuing operations before minority interest and incomes taxes			3,409				12,236				17,089				34,239
Minority interest share of earnings of consolidated subsidiaries			(2,287	)			(3,865	)			(9,703	)			(12,644	)
Income from continuing operations before income taxes			1,122				8,371				7,386				21,595
Income tax expense			536				3,469				2,998				8,917
Income from continuing operations			586				4,902				4,388				12,678
(Loss) income from discontinued operations, net of taxes			(90	)			6,870				3,936				7,843
Net income		$	496			$	11,772			$	8,324			$	20,521
Earnings per share, basic
Continuing operations		$	0.03			$	0.25			$	0.22			$	0.62
Discontinued operations			—				0.35				0.20				0.38
Earnings per share, basic		$	0.03			$	0.60			$	0.42			$	1.00
Earnings per share, diluted
Continuing operations		$	0.03			$	0.25			$	0.22			$	0.62
Discontinued operations			—				0.35				0.20				0.38
Earnings per share, diluted		$	0.03			$	0.60			$	0.42			$	1.00
Weighted average number of shares, basic			19,733				19,524				19,665				20,415
Dilutive effect of stock options and restricted stock			—				107				56				89
Weighted average number of shares, diluted			19,733				19,631				19,721				20,504

See notes to unaudited consolidated financial statements.

MEDCATH CORPORATION

CONSOLIDATED STATEMENT OF STOCKHOLDERS’ EQUITY

(In thousands)

(Unaudited)

																		Accumulated
																		Other
		Common Stock								Paid-in				Accumulated				Comprehensive				Treasury Stock
		Shares				Par Value				Capital				Deficit				(Loss)				Shares				Amount				Total
Balance, September 30, 2008			21,553			$	216			$	455,494			$	(41,138	)		$	(179	)			1,954			$	(44,797	)		$	369,596
Stock awards, including income tax benefit			139				—				(2,216	)			—				—				—				—				(2,216	)
Share-based compensation expense			—				—				2,068				—				—				—				—				2,068
Comprehensive income:
Net income			—				—				—				8,324				—				—				—				8,324
Change in fair value of interest rate swap, net of income tax benefit			—				—				—				—				(147	)			—				—				(147	)
Total comprehensive income																															8,177
Balance, June 30, 2009			21,692			$	216			$	455,346			$	(32,814	)		$	(326	)			1,954			$	(44,797	)		$	377,625

See notes to unaudited consolidated financial statements.

MEDCATH CORPORATION

CONSOLIDATED STATEMENTS OF CASH FLOWS

(In thousands)

(Unaudited)

		Nine Months Ended June 30,
		2009				2008
Net income		$	8,324			$	20,521
Adjustments to reconcile net income to net cash provided by operating activities:
Income from discontinued operations, net of taxes			(3,936	)			(7,843	)
Bad debt expense			34,558				31,852
Depreciation			23,258				22,535
Amortization			589				411
Excess income tax benefit on stock awards and options			—				(648	)
Loss on disposal of property, equipment and other assets			138				391
Share-based compensation expense			2,068				5,463
Loss on early extinguishment of debt			6,702				—
Amortization of loan acquisition costs			784				659
Equity in earnings of unconsolidated affiliates, net of distributions received			1,470				(536	)
Minority interest share of earnings of consolidated subsidiaries			9,703				12,644
Other			(34	)			—
Deferred income taxes			58				(1,846	)
Change in assets and liabilities that relate to operations:
Accounts receivable			(26,888	)			(37,238	)
Medical supplies			(2,856	)			(1,737	)
Prepaids and other assets			(2,252	)			1,188
Accounts payable and accrued liabilities			3,040				(10,347	)
Net cash provided by operating activities of continuing operations			54,726				35,469
Net cash (used in) provided by operating activities of discontinued operations			(1,205	)			521
Net cash provided by operating activities			53,521				35,990
Investing activities:
Purchases of property and equipment			(72,399	)			(38,127	)
Proceeds from sale of property and equipment			856				358
Investments in affiliates			—				(9,532	)
Return of investment in affiliates			307				—
Net cash used in investing activities of continuing operations			(71,236	)			(47,301	)
Net cash provided by investing activities of discontinued operations			6,895				76,225
Net cash (used in) provided by investing activities			(64,341	)			28,924
Financing activities:
Proceeds from issuance of long-term debt			83,479				—
Repayments of long-term debt			(115,515	)			(2,144	)
Repayments of obligations under capital leases			(949	)			(1,024	)
Distributions to minority partners			(12,175	)			(14,813	)
Proceeds from exercised stock options			77				3,947
Purchase of treasury shares			—				(44,403	)
Excess income tax benefit on stock awards and options			—				648
Net cash used in financing activities of continuing operations			(45,083	)			(57,789	)
Net cash used in financing activities of discontinued operations			(3,256	)			(14,745	)
Net cash used in financing activities			(48,339	)			(72,534	)
Net (decrease) increase in cash and cash equivalents			(59,159	)			(7,620	)
Cash and cash equivalents:
Beginning of period			112,068				145,385
End of period		$	52,909			$	137,765
Cash and cash equivalents of continuing operations			42,857				120,735
Cash and cash equivalents of discontinued operations			10,052				17,030

See notes to unaudited consolidated financial statements

MEDCATH CORPORATION

NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS
(All tables in thousands, except percentages and per share data)

1. Business and Basis of Presentation

     MedCath Corporation (the “Company”) primarily focuses on providing high acuity services, predominantly the diagnosis and treatment of cardiovascular disease. The Company owns and operates hospitals in partnership with physicians, most of whom are cardiologists and cardiovascular surgeons. While each of the Company’s majority-owned hospitals (collectively, the “Hospital Division”) is licensed as a general acute care hospital, the Company focuses on serving the unique needs of patients suffering from cardiovascular disease. As of June 30, 2009, the Company and its physician partners have ownership interest in and operate nine hospitals in seven states with a total of 755 licensed beds.

     In addition to its hospitals, the Company provides cardiovascular care services in diagnostic and therapeutic facilities in various locations and through mobile cardiac catheterization laboratories (the “MedCath Partners Division”). The Company also provides consulting and management services tailored primarily to cardiologists and cardiovascular surgeons, which is included in the Corporate and other division.

     The Company accounts for all but two of its owned and operated hospitals as consolidated subsidiaries. The Company owns a minority interest in the Avera Heart Hospital of South Dakota and Harlingen Medical Center as of June 30, 2009 and is not the primary beneficiary under the revised version of Financial Accounting Standards Board (“FASB”) Interpretation No. 46, Consolidation of Variable Interest Entities, an interpretation of ARB No. 51 (“FIN No. 46-R”). Therefore, the Company is unable to consolidate these hospitals’ results of operations and financial position, but rather is required to account for its minority ownership interest in these hospitals as an equity method investment in accordance with Accounting Principles Board Opinion No. 18, The Equity Method of Accounting for Investments in Common Stock , see Note 5.

      Basis of Presentation — The Company’s unaudited interim consolidated financial statements as of June 30, 2009 and for the three and nine months ended June 30, 2009 and 2008 have been prepared in accordance with accounting principles generally accepted in the United States of America hereafter, (generally accepted accounting principles) and pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”). These unaudited interim consolidated financial statements reflect, in the opinion of management, all material adjustments necessary to fairly state the results of operations and financial position for the periods presented. All intercompany transactions and balances have been eliminated.

     Certain information and disclosures normally included in the notes to consolidated financial statements have been condensed or omitted as permitted by the rules and regulations of the SEC, although the Company believes the disclosures are adequate to make the information presented not misleading. The unaudited interim consolidated financial statements and notes thereto should be read in conjunction with the Company’s audited consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended September 30, 2008. During the nine months ended June 30, 2009, the Company has not made any material changes in the selection or application of its critical accounting policies that were set forth in its Annual Report on Form 10-K for the fiscal year ended September 30, 2008.

2. Recent Accounting Pronouncements

      Recently Adopted Accounting Pronouncements:

     Effective October 1, 2008 the Company adopted the provisions of Statement of Financial Accounting Standards No. 157, Fair Value Measures (“SFAS 157”). SFAS 157 defines fair value, establishes a framework for measuring fair value and enhances disclosures about fair value measures required under other accounting pronouncements, but does not change existing guidance as to whether or not an instrument is carried at fair value. In February 2008, the Financial Accounting Standards Board (“FASB”) issued FASB Staff Position (“FSP”) Financial Accounting Standard (“FAS”) 157-1, Application of FASB Statement No. 157 to FASB Statement No. 13 and Its Related Interpretive Accounting Pronouncements That Address Leasing Transactions , and FSP FAS 157-2, Effective Date of FASB Statement No. 157 . FSP FAS 157-1 removes leasing from the scope of SFAS No. 157. FSP FAS 157-2 delays the effective date of SFAS No. 157 for all nonfinancial assets and nonfinancial liabilities, except those that are recognized or disclosed at fair value in the financial statements on a recurring basis (at least annually). In accordance with the provisions of FSP FAS 157-2 the Company has elected to defer implementation of SFAS 157 until October 1, 2010 as it relates to the Company’s non-financial assets and non-financial liabilities that are not permitted or required to be measured at fair value on a recurring basis. The Company is evaluating the impact, if any, SFAS 157 will have on those non-financial assets and liabilities. The adoption of SFAS 157, in regard to financial assets and liabilities, did not have any impact on the Company’s consolidated balance sheets, results of operations or cash flows, as the Company did not have any financial assets or liabilities that are required to be re-measured and reported at fair value as of and for the nine months ended June 30, 2009.

     Effective October 1, 2008 the Company adopted the provisions of Statements of Financial Accounting Standards No. 159, The Fair Value Option for Financial Assets and Financial Liabilities (“SFAS 159”). SFAS 159 permits entities to choose to measure eligible items at fair value at specified election dates and report unrealized gains and losses on items for which the fair value option has been elected in earnings at each subsequent reporting date. The Company has elected not to apply the fair value option to any “eligible items”, as defined by SFAS 159.

MEDCATH CORPORATION
NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS — Continued

     Effective June 30, 2009 the Company adopted the provisions of FSP SFAS 107-1 and APB 28-1, Interim Disclosures about Fair Value of Financial Instruments (“FSP SFAS No. 107-1 and APB 28-1”). FSP SFAS No. 107-1 and APB 28-1, amend SFAS No. 107, Disclosures about Fair Value of Financial Instruments and APB Opinion No. 28, Interim Financial Reporting to require disclosures of the fair value of financial instruments in interim financial statements. See Note 6 for further disclosures.

     Effective June 30, 2009 the Company adopted the provisions of Statements of Financial Accounting Standards No. 165, Subsequent Events (“SFAS 165”). SFAS 165 establishes general standards of accounting for and disclosure of events that occur after the balance sheet date but before financial statements are issued or are available to be issued. In particular, SFAS No. 165 sets forth the following: (i) the period after the balance sheet date during which management of a reporting entity should evaluate events or transactions that may occur for potential recognition or disclosure in the financial statements; (ii) the circumstances under which an entity should recognize events or transactions occurring after the balance sheet date in its financial statements; and (iii) the disclosures that an entity should make about events or transactions that occurred after the balance sheet date. See Note 13 for further disclosures.

     Effective June 30, 2009 the Company adopted the provisions of FSP SFAS 115-2 and SFAS 124-2 Recognition and Presentation of Other-Than-Temporary Impairments (“FSP SFAS 115-2 and SFAS 124-2”), which modifies the existing other than temporary impairments (“OTTI”) model for investments in debt securities. Under FSP SFAS 115-2 and SFAS 124-2, the primary change to the OTTI model for debt securities is the change in focus from an entity’s intent and ability to hold a security until recovery. Instead, an OTTI is triggered if (1) an entity has the intent to sell the security, (2) it is more likely than not that it will be required to sell the security before recovery, or (3) it does not expect to recover the entire amortized cost basis of the security. In addition, FSP SFAS 115-2 and SFAS 124-2 changes the presentation of an OTTI in the income statement if the only reason for recognition is a credit loss (i.e., an entity does not expect to recover its entire amortized cost basis). The adoption of FSP SFAS 115-2 and SFAS 124-2 did not have an impact on the Company’s consolidated balance sheets, results of operations or cash flows.

     Effective June 30, 2009 the Company adopted the provisions of FSP SFAS 157-4 Determining Fair Value When the Volume and Level of Activity for the Asset or Liability Have Significantly Decreased and Identifying Transactions That Are Not Orderly (“FSP SFAS 157-4”), which provides guidance on (1) estimating the fair value of an asset or liability (financial and nonfinancial) when the volume and level of activity for the asset or liability have significantly decreased and (2) identifying transactions that are not orderly. The adoption of FSP SFAS 157-4 did not have an impact on the Company’s consolidated balance sheets, results of operations or cash flows.

      Recently Issued Accounting Pronouncements:

     On June 12, 2009, the FASB issued Statement of Financial Accounting Standards No. 167, Amendments to FASB Interpretation No, 46(R) (“SFAS 167”), which amends the consolidation guidance that applies to variable interest entities (“VIE”s). The amendments will significantly affect the overall consolidation analysis under FIN No. 46-R. The provisions of SFAS 167 revise the definition and consideration of VIEs, primary beneficiary, and triggering events in which a company must re-evaluate its conclusions as to the consolidation of an entity under the provisions of SFAS 167. SFAS 167 is effective as of the beginning of the first fiscal year after November 15, 2009, fiscal 2011 for the Company. The Company is evaluating the potential impacts the adoption of SFAS 167 will have on its consolidated financial statements.

     On June 29, 2009, the FASB issued Statement of Financial Accounting Standards No. 168, The FASB Accounting Standards Codification and the Hierarchy of Generally Accepted Accounting Principles a replacement of FASB Statement No. 162 (“SFAS 168”). The FASB Accounting Standards Codification (the “Codification”) will become the source of authoritative U.S. generally accepted accounting principles (“GAAP”) recognized by the FASB to be applied by nongovernmental entities. Rules and interpretive releases of the SEC under authority of federal securities laws are also sources of authoritative GAAP for SEC registrants, such as the Company. On the effective date of SFAS 168, the Codification will supersede all then-existing non-SEC accounting and reporting standards. All other nongrandfathered non-SEC accounting literature not included in the Codification will become nonauthoritative. SFAS 168 is effective for financial statements issued for interim and annual periods ending after September 15, 2009. The Company does not anticipate the adoption of SFAS 168 will have a material impact on its consolidated financial statements.

3. Divestitures

     During December 2008 the MedCath Partners Division of the Company sold its entire interest in Cape Cod Cardiology Services, LLC (“Cape Cod”) for $6.9 million, resulting in a gain of $4.0 million, net of tax, which has been included in income from discontinued operations for the nine months ended June 30, 2009.

     During May 2008 the Hospital Division of the Company sold the net assets of Dayton Heart Hospital (“DHH”). In accordance with Statement of Financial Accounting Standards No. 144, Accounting for the Impairment or Disposal of Long-Lived Assets (“SFAS 144”) the Company has classified the results of operations and the impacts from the collections and payments of the remaining assets and liabilities associated with the facilities divested, as discontinued operations for the three and nine months ended June 30, 2009 and 2008.

MEDCATH CORPORATION
NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS — Continued

     The results of operations and the assets and liabilities of discontinued operations included in the consolidated statements of income and consolidated balance sheets are as follows:

		Three Months Ended June 30,								Nine Months Ended June 30,
		2009				2008				2009				2008
Net revenue		$	78			$	9,260			$	1,910			$	48,233
Gain from sale of Cape Cod			—				—				6,640				—
(Loss) income before income taxes			(150	)			8,515				6,502				9,652
Income tax (benefit) expense			(60	)			1,645				2,566				1,809
Net (loss) income		$	(90	)		$	6,870			$	3,936			$	7,843

		June 30,				September 30,
		2009				2008
Cash and cash equivalents		$	10,052			$	18,232
Accounts receivable, net			—				1,856
Other current assets			—				688
Current assets of discontinued operations		$	10,052			$	20,776
Property and equipment, net		$	—			$	51
Long-term assets of discontinued operations		$	—			$	51
Accounts payable		$	9,559			$	9,467
Accrued liabilities			1				717
Current liabilities of discontinued operations		$	9,560			$	10,184

4. Accounts Receivable

     Accounts receivable, net, consists of the following:

		June 30,				September 30,
		2009				2008
Receivables, principally from patients and third-party payors		$	150,604			$	131,915
Receivables, principally from billings to hospitals for various cardiovascular procedures			1,131				2,608
Amounts due under management contracts			2,675				3,745
Other			5,540				3,463
			159,950				141,731
Less allowance for doubtful accounts			(83,745	)			(57,856	)
Accounts receivable, net		$	76,205			$	83,875

5. Equity Investments

     The Company owns minority interests in the Avera Heart Hospital of South Dakota, Harlingen Medical Center, and certain diagnostic ventures, for which the Company neither has substantive control over the ventures nor is the primary beneficiary. Therefore, the Company does not consolidate the results of operations and financial position of these entities, but rather accounts for its minority ownership interest in the hospitals and other ventures as equity method investments.

MEDCATH CORPORATION
NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS — Continued

     The following represents summarized combined financial information of the Company’s unconsolidated affiliates accounted for under the equity method:

		Three Months Ended June 30,								Nine Months Ended June 30,
		2009				2008				2009				2008
Net revenue		$	56,904			$	56,304			$	173,794			$	163,560
Income from operations		$	12,031			$	16,059			$	37,199			$	35,640
Net income		$	9,716			$	11,327			$	30,389			$	28,789

		June 30,				September 30,
		2009				2008
Current assets		$	62,139			$	70,921
Long-term assets		$	153,168			$	153,766
Current liabilities		$	30,589			$	28,958
Long-term liabilities		$	116,896			$	123,356

6. Long-Term Debt

     Long-term debt consists of the following:

		June 30,				September 30,
		2009				2008
Senior Notes		$	—			$	101,961
Senior Secured Credit Facility			80,000				—
Notes payable to various lenders			42,146				44,415
			122,146				146,376
Less current portion			(17,463	)			(30,748	)
Long-term debt		$	104,683			$	115,628

     During November 2008, the Company amended and restated its senior secured credit facility (the “Senior Secured Credit Facility”). The Senior Secured Credit Facility provides for a three-year term loan facility in the amount of $75.0 million (the “Term Loan”) and a revolving credit facility in the amount of $85.0 million (the “Revolver”), which includes a $25.0 million sub-limit for the issuance of stand-by and commercial letters of credit and a $10.0 million sub-limit for swing-line loans. At the request of the Company and approval from its lenders, the aggregate amount available under the Senior Secured Credit Facility may be increased by an amount up to $50.0 million. Borrowings under the Senior Secured Credit Facility, excluding swing-line loans, bear interest per annum at a rate equal to the sum of LIBOR plus the applicable margin or the alternate base rate plus the applicable margin. At June 30, 2009 the Term Loan bore interest at 3.32% and the Revolver bore interest at 2.82%.

     The Senior Secured Credit Facility continues to be guaranteed jointly and severally by the Company and certain of the Company’s existing and future, direct and indirect, wholly owned subsidiaries and continues to be secured by a first priority perfected security interest in all of the capital stock or other ownership interests owned by the Company and subsidiary guarantors in each of their subsidiaries, and, subject to certain exceptions in the credit facility, all other present and future assets and properties of the Company and the subsidiary guarantors and all intercompany notes.

     The Senior Secured Credit Facility requires compliance with certain financial covenants including a consolidated senior secured leverage ratio test, a consolidated fixed charge coverage ratio test and a consolidated total leverage ratio test. The Senior Secured Credit Facility also contains customary restrictions on, among other things, the Company and subsidiaries’ ability to incur liens; engage in mergers, consolidations and sales of assets; incur debt; declare dividends; redeem stock and repurchase, redeem and/or repay other debt; make loans, advances and investments and acquisitions; and enter into transactions with affiliates.

     The Senior Secured Credit Facility contains events of default, including cross-defaults to certain indebtedness, change of control events, and other events of default customary for syndicated commercial credit facilities. Upon the occurrence of an event of default, the Company could be required to immediately repay all outstanding amounts under the amended credit facility.

MEDCATH CORPORATION
NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS — Continued

     The Company is required to make mandatory prepayments of principal in specified amounts upon the occurrence of certain events identified in the Senior Secured Credit Facility and is permitted to make voluntary prepayments of principal under the Senior Secured Credit Facility. The Term Loan is subject to amortization of principal in quarterly installments commencing on March 31, 2010. The maturity date of both the Term Loan and the Revolver is November 10, 2011. The maximum availability under the revolver is reduced by $5.0 million of outstanding borrowings and $3.5 million of outstanding letters of credit.

     During December 2008 the Company redeemed its outstanding 9 7/8% senior notes (the “Senior Notes”) issued by MedCath Holdings Corp., a wholly owned subsidiary of the Company, for $111.2 million, which included the payment of a repurchase premium of $5.0 million and accrued interest of $4.2 million. The Senior Notes were redeemed through borrowings under the Senior Secured Credit Facility and available cash on hand. In addition to the aforementioned repurchase premium the Company incurred $2.0 million in expense related to the write-off of previously incurred financing costs associated with the Senior Notes. The repurchase premium and write off of previously incurred financing costs have been included in the consolidated statement of income as loss on early extinguishment of debt.

      Debt Covenants —At June 30, 2009, the Company was in violation of financial covenants under equipment loans at Texsan Heart Hospital. Accordingly, the total outstanding balance of $6.8 million for these loans has been included in the current portion of long-term debt and obligations under capital leases on the Company’s consolidated balance sheet. The covenant violations did not result in any other non-compliance related to the remaining covenants governing the Company’s outstanding debt; thereby the Company remained in compliance with all other covenants.

      Fair Value of Financial Instruments —The Company considers the carrying amount of significant classes of financial instruments on the consolidated balance sheets, including cash and cash equivalents; accounts receivable, net, accounts payable; income taxes payable; accrued liabilities; variable rate long-term debt; obligations under capital leases; and other long-term obligations to be reasonable estimates of fair value due either to their length to maturity or the existence of variable interest rates underlying such financial instruments that approximate prevailing market rates at June 30, 2009 and September 30, 2008. The estimated fair value of long-term debt, including the current portion, at June 30, 2009 is approximately $40.0 million as compared to a carrying value of approximately $42.1 million. At September 30, 2008, the estimated fair value of long-term debt, including the current portion, was approximately $152.8 million as compared to a carrying value of approximately $146.4 million. Fair value of the Company’s fixed rate debt was estimated using discontinued cash flow analyses, based on the Company’s current incremental borrowing rates for similar types of arrangements and market information. The fair value of the Company’s variable rate debt was determined to approximate its carrying value, due to the underlying variable interest rates.

7. Contingencies and Commitments

      Contingencies — The Medicare and Medicaid programs are subject to statutory and regulatory changes, retroactive and prospective rate adjustments, administrative rulings, court decisions, executive orders and freezes and funding reductions, all of which may significantly affect the Company. In addition, reimbursement is generally subject to adjustment following audit by third party payors, including the fiscal intermediaries who administer the Medicare program, the Centers for Medicare and Medicaid Services (“CMS”). Final determination of amounts due providers under the Medicare program often takes several years because of such audits, as well as resulting provider appeals and the application of technical reimbursement provisions. The Company believes that adequate provisions have been made for any adjustments that might result from these programs; however, due to the complexity of laws and regulations governing the Medicare and Medicaid programs, the manner in which they are interpreted and the other complexities involved in estimating net revenue, there is a possibility that recorded estimates will change by a material amount in the future.

     In 2005, CMS began using recovery audit contractors (“RACs”) to detect Medicare overpayments not identified through existing claims review mechanisms. The RAC program relies on private auditing firms to examine Medicare claims filed by healthcare providers. Fees to the RACs are paid on a contingency basis. The RAC program began as a demonstration project in 2005 in three states (New York, California and Florida) which was expanded into the three additional states of Arizona, Massachusetts and South Carolina in July 2007. No RAC audits, however, were initiated at the Company’s Arizona or California hospitals during the demonstration project. The program was made permanent by the Tax Relief and Health Care Act of 2006 enacted in December 2006. CMS announced in March 2008 the end of the demonstration project and the commencement of the permanent program by the expansion of the RAC program to additional states beginning in the summer and fall 2008 and its plans to have RACs in place in all 50 states by 2010.

     RACs perform post-discharge audits of medical records to identify Medicare overpayments resulting from incorrect payment amounts, non-covered services, incorrectly coded services, and duplicate services. CMS has given RACs the authority to look back at claims up to three years old, provided that the claim was paid on or after October 1, 2007. Claims identified as overpayments will be subject to the Medicare appeals process.

     The Company believes the claims for reimbursement submitted to the Medicare program by the Company’s facilities have been accurate, however the Company is unable to reasonably estimate what the potential result of future RAC audits or other reimbursement matters could be.

MEDCATH CORPORATION
NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS — Continued

     The Company is involved in various claims and legal actions in the ordinary course of business, including malpractice claims arising from services provided to patients that have been asserted by various claimants and additional claims that may be asserted for known incidents through June 30, 2009. These claims and legal actions are in various stages, and some may ultimately be brought to trial. Moreover, additional claims arising from services provided to patients in the past and other legal actions may be asserted in the future. The Company is protecting its interests in all such claims and actions and does not expect the ultimate resolution of these matters to have a material adverse impact on the Company’s consolidated financial position, results of operations or cash flows.

     A joint venture in our MedCath Partners Division provides cardiac care services to a hospital pursuant to a management and services agreement. The joint venture and the hospital disagreed regarding the interpretation of certain provisions in the management and services agreement. During August 2008 the two parties reached an agreement as to settlement, resulting in the Company recording a liability of $0.7 million which is included within accrued liabilities in the consolidated balance sheet at September 30, 2008. During November 2008 the entire settlement amount was paid by the Company.

     During the prior and current fiscal year, the Company refunded certain reimbursements to CMS related to carotid artery stent procedures performed during prior fiscal years at two of the Company’s consolidated subsidiary hospitals. The U.S. Department of Justice (“DOJ”) initiated an investigation related to the Company’s return of these reimbursements. As a result of the DOJ’s investigation, the Company began negotiating a settlement agreement during the third quarter of fiscal 2009 with the DOJ whereby the Company is expected to pay approximately $0.8 million to settle and obtain a release from any federal civil false claims liability related to DOJ’s investigation. The DOJ allegations do not involve patient care, and relate solely to whether the procedures were properly reimbursable by Medicare. The settlement would not include any finding of wrong-doing or any admission of liability. As part of the settlement, the Company is also negotiating with the Department of Health and Human Services, Office of Inspector General, (“OIG”), to obtain a release from any federal health care program permissive exclusion actions to be instituted by the OIG. As of June 30, 2009 Company accrued the $0.8 million within other accrued liabilities on the consolidated balance sheet.

     The Company has a one year claims-made policy providing coverage for medical malpractice claim amounts in excess of $2.0 million of retained liability per claim. The Company additionally has insurance to reduce the retained liability per claim to $250,000 for the MedCath Partners division. Due to the Company’s self-insured retention levels, the Company is required to recognize an estimated liability for the amount of retained liability applicable to each malpractice claim. As of June 30, 2009 and September 30, 2008, the total estimated liability for the Company’s self-insured retention on medical malpractice claims, including an estimated amount for incurred but not reported claims, was approximately $5.4 million and $4.6 million, respectively, which is included in other accrued liabilities in the consolidated balance sheets.

     In addition to reserves for medical malpractice, the Company also maintains reserves for self-insured workman’s compensation, healthcare and dental coverage. The total estimated reserve for self-insured liabilities for workman’s compensation, employee health and dental claims was $3.2 million as of June 30, 2009 and September 30, 2008 which is included in other accrued liabilities in the consolidated balance sheets. The Company maintains this reserve based on historical experience with claims. The Company maintains commercial stop loss coverage for health and dental insurance program of $175,000 per plan participant.

      Commitments — The Company’s hospitals provide guarantees to certain physician groups for funds required to operate and maintain services for the benefit of the hospital’s patients including emergency care services and anesthesiology services, among other services, which are accounted in accordance with Interpretation No. 45-3, Application of FASB Interpretation No. 45 to Minimum Revenue Guarantees Granted to a Business or Its Owners issued by the FASB. As of June 30, 2009, the maximum potential future payments that the Company could be required to make under these guarantees were approximately $26.5 million through July 2012. At June 30, 2009 the Company had a liability of $12.4 million for the fair value of these guarantees, of which $6.0 million is in other accrued liabilities and $6.4 million is in other long term obligations. Additionally, the Company had an asset of $12.3 million representing the future services to be provided by the physicians, of which $5.9 million is in prepaid expenses and other current assets and $6.4 million is in other assets.

8. Per Share Data

     The calculation of diluted earnings per share considers the potential dilutive effect of options to purchase 1,205,587 and 1,810,614 shares of common stock at prices ranging from $4.75 to $33.05, which were outstanding at June 30, 2009 and 2008, respectively, as well as 487,335 and 145,430 shares of restricted stock which were outstanding at June 30, 2009 and 2008, respectively. Of the outstanding stock options and restricted stock 1,692,922 and 1,501,000 have not been included in the calculation of diluted earnings per share for the three months ended June 30, 2009 and 2008, respectively, and 1,637,260 and 786,000 have not been included in the calculation of diluted earnings per share for the nine months ended June 30, 2009 and 2008, respectively, because the stock options and restricted stock were anti-dilutive.

MEDCATH CORPORATION
NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS — Continued

9. Stock Based Compensation

     The Company accounts for stock-based compensation under the provisions of SFAS No. 123(R), Share-Based Payment (“SFAS 123(R)”). SFAS 123(R) established accounting for stock-based awards exchanged for employee and certain nonemployee services. Accordingly, for employee awards, equity classified stock-based compensation cost is measured at the grant date, based on the fair value of the award, and is recognized as expense over the requisite service period. Stock based compensation expense recorded during the three and nine months ended June 30, 2009 was $0.2 million and $2.1 million, respectively. Tax benefits generated from stock based compensation expense was $0.1 million and $0.8 million for the three and nine months ended June 30, 2009, respectively. Stock based compensation expense recognized for the three and nine months ended June 30, 2008 was $1.5 million and $5.5 million, respectively. Tax benefits generated from stock based compensation expense was $0.6 million and $2.2 million for the three and nine months ended June 30, 2008, respectively.

      Stock Options

     The following table summarizes the Company’s stock option activity:

		For the Three Months Ended
		June 30, 2009								June 30, 2008
						Weighted-								Weighted-
		Number of				Average				Number of				Average
		Stock Options				Exercise Price				Stock Options				Exercise Price
Outstanding stock options, beginning of period			1,302,587			$	21.60				1,802,112			$	22.03
Granted			—				—				149,000				19.92
Exercised			(7,000	)			10.95				(72,748	)			12.79
Cancelled			(90,000	)			21.60				(67,750	)			26.23
Outstanding stock options, end of period			1,205,587			$	21.66				1,810,614			$	22.07

		For the Nine Months Ended
		June 30, 2009								June 30, 2008
						Weighted-								Weighted-
		Number of				Average				Number of				Average
		Stock Options				Exercise Price				Stock Options				Exercise Price
Outstanding stock options, beginning of period			1,776,837			$	22.15				1,727,112			$	19.11
Granted			82,000				17.46				480,000				24.51
Exercised			(7,000	)			10.95				(252,748	)			20.16
Cancelled			(646,250	)			22.59				(143,750	)			27.02
Outstanding stock options, end of period			1,205,587			$	21.66				1,810,614			$	22.07

      Restricted Stock Awards

     During the three and nine months ended June 30, 2009, the Company granted to employees 96,725 and 520,878 shares of restricted stock, respectively. Restricted stock granted to employees, excluding executives of the Company, vest in equal annual installments over a three year period. Executives of the Company, defined by the Company as vice president or higher, received two separately equal grants. The first grant of restricted stock vests in equal annual installments over a three year period, the second grant of restricted stock vests over a three year period based on established performance conditions. During the second quarter of this fiscal year, the Company granted 95,900 shares of restricted stock units to directors, which were fully vested at the date of grant but have certain sales restrictions. Compensation expense, derived from the market price of the Company’s stock at the date of grant, less estimated forfeitures, is recognized on a straight-line basis over the vesting period. At June 30, 2009 the Company had $2.8 million of unrecognized compensation expense associated with restricted stock awards .

MEDCATH CORPORATION
NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS — Continued

     The following table summarizes the Company’s restricted stock award activity:

		For the Three Months Ended
		June 30, 2009								June 30, 2008
		Number of				Weighted-				Number of				Weighted-
		Restricted				Average				Restricted				Average
		Stock Units				Grant Price				Stock Units				Grant Price
Outstanding restricted stock units, beginning of period			559,116			$	9.74				154,508			$	19.52
Granted			96,725				9.42				—				—
Vested			—				—				(21,448	)			20.50
Cancelled			(72,606	)			9.40				(9,078	)			20.50
Outstanding restricted stock units, end of period			583,235			$	9.73				123,982			$	19.28

		For the Nine Months Ended
		June 30, 2009								June 30, 2008
		Number of				Weighted-				Number of				Weighted-
		Restricted				Average				Restricted				Average
		Stock Units				Grant Price				Stock Units				Grant Price
Outstanding restricted stock units, beginning of period			123,982			$	19.28				193,982			$	19.72
Granted			616,778				9.01				—				—
Vested			(52,106	)			20.50				(21,448	)			20.50
Cancelled			(105,419	)			11.42				(48,552	)			20.50
Outstanding restricted stock units, end of period			583,235			$	9.73				123,982			$	19.28

MEDCATH CORPORATION
NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS — Continued

10. Reportable Segment Information

     The Company’s reportable segments consist of the Hospital Division and the MedCath Partners Division.

     Financial information concerning the Company’s operations by each of the reportable segments as of and for the periods indicated is as follows:

		Three Months Ended June 30,								Nine Months Ended June 30,
		2009				2008				2009				2008
Net revenue:
Hospital Division		$	143,399			$	145,663			$	439,635			$	428,876
MedCath Partners Division			7,398				8,040				22,931				24,484
Corporate and other			107				570				308				1,808
Consolidated totals		$	150,904			$	154,273			$	462,874			$	455,168
Income (loss) from operations:
Hospital Division		$	3,271			$	14,777			$	26,526			$	63,488
MedCath Partners Division			795				288				2,210				2,385
Corporate and other			(1,823	)			(1,887	)			(6,868	)			(28,748	)
Consolidated totals		$	2,243			$	13,178			$	21,868			$	37,125

		June 30,				September 30,
		2009				2008
Aggregate identifiable assets:
Hospital Division		$	570,377			$	546,665
MedCath Partners Division			33,694				38,719
Corporate and other			33,313				68,072
Consolidated totals		$	637,384			$	653,456

     Substantially all of the Company’s net revenue in its Hospital Division and MedCath Partners Division is derived directly or indirectly from patient services. The amounts presented for Corporate and other primarily include management and consulting fees, general overhead and administrative expenses, financing activities, certain cash and cash equivalents, prepaid expenses, and other assets and operations of the business not subject to separate segment reporting.

11. Goodwill and Intangible Assets

     Goodwill represents acquisition costs in excess of the fair value of net identifiable tangible and intangible assets. All of the Company’s goodwill is recorded within the Hospital Division segment. The Company evaluates goodwill annually on September 30 or earlier if indicators of potential impairment exist. Due to market conditions during the first quarter of 2009 and the related decline in the Company’s market capitalization, the Company performed an interim impairment test as of December 31, 2008. The results of this interim test indicated that no impairment existed as of that date.

     The determination of whether goodwill has become impaired involves a significant level of judgment in the assumptions underlying the approach used to determine the fair value of the Company’s reporting unit. Changes in the Company’s strategy, assumptions and/or market conditions could significantly impact these judgments. Additionally, certain legislation is currently pending which could potentially impact the Company. Management will continue to monitor market conditions as well as pending legislation to determine if additional interim impairment tests are necessary in future periods. If impairment indicators are determined to be present in such periods, the resulting impairment charges could be material. There were no such indicators during the second or third quarter of this current fiscal year.

MEDCATH CORPORATION
NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS — Continued

12. Comprehensive Income

		Three Months Ended June 30,								Nine Months Ended June 30,
		2009				2008				2009				2008
Net Income		$	496			$	11,772			$	8,324			$	20,521
Changes in fair value of interest rate swaps, net of tax benefit			126				146				(147	)			(99	)
Comprehensive Income		$	622			$	11,918			$	8,177			$	20,422

13. Subsequent Events

The Company has evaluated events subsequent to June 30, 2009 through August 7, 2009, the date the Company filed such unaudited consolidated financial statements on Form 10-Q with the SEC, and determined that no material subsequent events have occurred.

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

      The following discussion and analysis of our financial condition and results of operations should be read in conjunction with the interim unaudited consolidated financial statements and related notes included elsewhere in this report, as well as the audited consolidated financial statements and related notes thereto and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” included in our Annual Report on Form 10-K for the fiscal year ended September 30, 2008.

Overview

      General . We are a healthcare provider focused primarily on providing high acuity services, predominantly the diagnosis and treatment of cardiovascular disease. We own and operate hospitals in partnership with physicians whom we believe have established reputations for clinical excellence. We have ownership interests in and operate nine hospitals, with a total of 755 licensed beds, of which 705 are staffed and available, and are located predominately in high growth markets in seven states: Arizona, Arkansas, California, Louisiana, New Mexico, South Dakota, and Texas . We are currently in the process of developing a new hospital in Kingman, Arizona. We expect this hospital to open in late 2009 or early 2010. This hospital is designed to accommodate a total of 106 licensed beds and will initially open with 70 licensed beds. We completed our 79 bed expansion at Louisiana Medical Center and Heart Hospital during May 2009, with remaining capacity for an additional 40 beds at that hospital. We also have plans to expand our Bakersfield Heart Hospital by 72 inpatient beds and 16 emergency department beds that will diversify the services offered by that hospital.

     In addition to our hospitals, we currently own and/or manage 19 cardiac diagnostic and therapeutic facilities. Twelve of these facilities are located at hospitals operated by other parties. These facilities offer invasive diagnostic and, in some cases, therapeutic procedures. The remaining seven facilities are not located at hospitals and offer only diagnostic procedures.

      Revenue Sources by Division. The largest percentage of our net revenue is attributable to our Hospital Division. The following table sets forth the percentage contribution of each of our consolidating divisions to consolidated net revenue in the periods indicated below.

		Three Months Ended June 30,								Nine Months Ended June 30,
Division		2009				2008				2009				2008
Hospital			95.0	%			94.4	%			95.0	%			94.2	%
MedCath Partners			4.9	%			5.2	%			4.9	%			5.4	%
Corporate and other			0.1	%			0.4	%			0.1	%			0.4	%
Net Revenue			100.0	%			100.0	%			100.0	%			100.0	%

      Revenue Sources by Payor. We receive payments for our services rendered to patients from the Medicare and Medicaid programs, commercial insurers, health maintenance organizations and patients directly. Our net revenue is determined by a number of factors, including the payor mix, the number and nature of procedures performed and the rate of payment for the procedures. Since cardiovascular disease disproportionately affects those age 55 and older, the proportion of net revenue we derive from the Medicare program is higher than that of most general acute care hospitals. The following table sets forth the percentage of consolidated net revenue we earned by category of admitting payor in the periods indicated.

		Three Months Ended June 30,								Nine Months Ended June 30,
Payor		2009				2008				2009				2008
Medicare			49.7	%			51.2	%			51.9	%			52.0	%
Medicaid			1.9	%			2.8	%			3.0	%			3.1	%
Commercial and other, including self-pay			48.4	%			46.0	%			45.1	%			44.9	%
Total consolidated net revenue			100.0	%			100.0	%			100.0	%			100.0	%

     A significant portion of our net revenue is derived from federal and state governmental healthcare programs, including Medicare and Medicaid, and we expect the net revenue that we receive from the Medicare program as a percentage of total consolidated net revenue will remain significant in future periods. Our payor mix may fluctuate in future periods due to changes in reimbursement, market and industry trends with self-pay patients, and other similar factors.

     The Medicare and Medicaid programs are subject to statutory and regulatory changes, retroactive and prospective rate adjustments, administrative rulings, court decisions, executive orders and freezes and funding reductions, all of which may significantly affect our business. In addition, reimbursement is generally subject to adjustment following audit by third party payors, including the fiscal intermediaries who administer the Medicare program, i.e. the CMS. Final determination of amounts due providers under the Medicare program often takes several years because of such audits, as well as resulting provider appeals and the application of technical reimbursement provisions. We believe that adequate provision has been made for any adjustments that might result from these programs; however, due to the complexity of laws and regulations governing the Medicare and Medicaid programs, the manner in which they are interpreted and the other complexities involved in estimating our net revenue, there is a possibility that recorded estimates will change by a material amount in the future.

     In 2005, CMS began using RACs to detect Medicare overpayments not identified through existing claims review mechanisms. The RAC program relies on private auditing firms to examine Medicare claims filed by healthcare providers. Fees to the RACs are paid on a contingency basis. The RAC program began as a demonstration project in 2005 in three states (New York, California and Florida) which was expanded into the three additional states of Arizona, Massachusetts and South Carolina in July 2007. No RAC audits, however, were initiated at our Arizona or California hospitals during the demonstration project. The program was made permanent by the Tax Relief and Health Care Act of 2006 enacted in December 2006. CMS announced in March 2008 the end of the demonstration project and the commencement of the permanent program by the expansion of the RAC program to additional states beginning in the summer and fall 2008 and its plans to have RACs in place in all 50 states by 2010.

     RACs perform post-discharge audits of medical records to identify Medicare overpayments resulting from incorrect payment amounts, non-covered services, incorrectly coded services, and duplicate services. CMS has given RACs the authority to look back at claims up to three years old, provided that the claim was paid on or after October 1, 2007. Claims identified as overpayments will be subject to the Medicare appeals process.

     Even though the Company believes the claims for reimbursement submitted to the Medicare program by the Company’s facilities have been accurate, the Company is unable to reasonably estimate what the potential result of future RAC audits or other reimbursement matters could be.

Results of Operations

Three Months Ended June 30, 2009 Compared to Three Months Ended June 30, 2008

      Statement of Operations Data . The following table presents our results of operations in dollars and as a percentage of net revenue for the periods indicated:

		Three Months Ended June 30,
		(in thousands except percentages)
										Increase/Decrease								% of Net Revenue
		2009				2008				$				%				2009				2008
Net revenue		$	150,904			$	154,273			$	(3,369	)			(2.2	)%			100.0	%			100.0	%
Operating expenses:
Personnel expense			50,862				50,520				342				0.7	%			33.7	%			32.8	%
Medical supplies expense			44,995				42,757				2,238				5.2	%			29.8	%			27.7	%
Bad debt expense			12,547				10,235				2,312				22.6	%			8.3	%			6.6	%
Other operating expenses			31,441				29,555				1,886				6.4	%			20.8	%			19.2	%
Pre-opening expenses			754				149				605				406.0	%			0.5	%			0.1	%
Depreciation			7,858				7,505				353				4.7	%			5.2	%			4.9	%
Amortization			230				149				81				54.4	%			0.2	%			0.1	%
(Gain) loss on disposal of property, equipment and other assets			(26	)			225				(251	)			111.6	%			(0.0	)%			0.1	%
Income from operations			2,243				13,178				(10,935	)			(83.0	)%			1.5	%			8.5	%
Other income (expenses):
Interest expense			(1,151	)			(3,862	)			2,711				70.2	%			(0.8	)%			(2.5	)%
Interest and other income, net			52				284				(232	)			(81.7	)%			0.0	%			0.2	%
Equity in net earnings of unconsolidated affiliates			2,265				2,636				(371	)			(14.1	)%			1.5	%			1.7	%
Income from continuing operations before minority interest, income taxes and discontinued operations			3,409				12,236				(8,827	)			(72.1	)%			2.2	%			7.9	%
Minority interest share of earnings of consolidated subsidiaries			(2,287	)			(3,865	)			1,578				40.8	%			(1.5	)%			(2.5	)%
Income from continuing operations before income taxes and discontinued operations			1,122				8,371				(7,249	)			(86.6	)%			0.7	%			5.4	%
Income tax expense			536				3,469				(2,933	)			(84.5	)%			0.3	%			2.2	%
Income from continuing operations			586				4,902				(4,316	)			(88.0	)%			0.4	%			3.2	%
(Loss) income from discontinued operations, net of taxes			(90	)			6,870				(6,960	)			(101.3	)%			(0.1	)%			4.4	%
Net income		$	496			$	11,772			$	(11,276	)			(95.8	)%			0.3	%			7.6	%

		Three Months Ended June 30,
		2009				2008%				Change
Selected Operating Data (a):
Number of hospitals			7				7
Licensed beds (b)			588				449
Staffed and available beds (c)			542				449
Admissions (d)			6,352				7,384				(14.0	)%
Adjusted admissions (e)			10,284				10,341				(0.6	)%
Patient days (f)			25,482				27,132				(6.1	)%
Adjusted patient days (g)			41,174				38,105				8.1	%
Average length of stay (days) (h)			4.01				3.67				9.3	%
Occupancy (i)			51.7	%			66.4	%
Inpatient catheterization procedures (j)			3,071				3,961				(22.5	)%
Inpatient surgical procedures (k)			2,045				2,260				(9.5	)%
Hospital net revenue (in thousands except percentages)		$	141,665			$	144,676				(2.1	)%

      Net Revenue. Our consolidated net revenue decreased 2.2% or $3.4 million to $150.9 million for the third quarter of fiscal 2009 from $154.3 million for the third quarter of fiscal 2008. Hospital Division net revenue decreased 2.1%, or $3.0 million, for the third quarter of fiscal 2009 compared to the same period of fiscal 2008, in addition to declines in our MedCath Partners division and Corporate and other.

     Over the past several quarters, our hospitals have experienced a shift in patient clinical setting from inpatient to outpatient as the result of advancement in medical technologies and at the direction of certain of our payors. Total inpatient net revenue was 66% of the Hospital Division’s total net patient revenue for the third quarter of fiscal 2009 compared to approximately 74% for the third quarter of fiscal 2008.

     Inpatient Hospital division net revenue decreased 13% in the third quarter of fiscal 2009 compared to the third quarter of fiscal 2008 and admissions declined 14% from 7,384 to 6,352. Inpatient net revenue declined for all of our core cardiovascular procedures with the exception of open heart procedures, which increased $0.9 million for the third quarter of fiscal 2009 compared to the third quarter of fiscal 2008. The overall decline in net patient revenue from our core cardiovascular procedures was partially offset by inpatient net revenue increases for new services performed at our hospitals such as digestive procedures.

     Outpatient Hospital division net revenue increased 26% in the third quarter of fiscal 2009 compared to the third quarter of fiscal 2008 and outpatient cases increased 13.1% from 16,183 to 18,302. Outpatient net revenue increased for all service lines with the exception of angioplasty procedures.

     Total net patient revenue related to drug eluting stent procedures and bare metal stent procedures, regardless of clinical setting, decreased $1.4 million, or 5.2%, for the third quarter of fiscal 2009 compared to the same quarter of fiscal 2008.

     Net revenue for the third quarter of fiscal 2008 included charity care deductions of $4.2 million compared to charity care deductions of $1.0 million for fiscal 2009. The reduction is the result of fewer patients applying and qualifying for charity discounts during the third quarter of fiscal 2009 compared to the same period of the prior year.

     Net revenue for the third quarter of fiscal 2009 was reduced by $3.1 million as a result of a reduction in the estimated amount of Medicare Disproportionate Share Hospital (“DSH”) payments certain hospitals are eligible for in prior periods. The primary method for a hospital to qualify for Medicare DSH reimbursement is based on a statutory formula that utilizes the percentage of inpatient days attributable to patients eligible for Medicaid, but not eligible for Medicare Part A, and a base formula called the Supplemental Security Income (“SSI”) percentage, which is released annually by the CMS. Based on the updated SSI percentage provided by CMS during June, 2009, we determined that four hospitals that we previously determined were eligible for DSH payments in fiscal 2007 and fiscal 2008 would either no longer be eligible for such payments or would be eligible for less payment than initially estimated.

      Personnel expense. Personnel expense increased 0.7% to $50.9 million for the third quarter of fiscal 2009 from $50.5 million for the third quarter of fiscal 2008. The $0.4 million increase in personnel expense was due primarily to annual merit increases and a corresponding increase in benefits offset by a $1.3 million reduction in stock compensation expense. Stock based compensation expense was $0.2 million for the third quarter of fiscal 2009 compared to $1.5 million for the third quarter of fiscal 2008. The stock based compensation expense for the third quarter of fiscal 2009 was recorded based on a vesting schedule related to the issuance of restricted shares to certain employees which vest over a three year period or vest 50% over a three year period and 50% over the same three year period if certain performance criteria are satisfied. The stock based compensation expense for the third quarter of fiscal 2008 was based on the issuance of stock options which vested immediately.

      Medical supplies expense. Medical supplies expense increased 5.2% to $45.0 million for the third quarter of fiscal 2009 from $42.8 million for the third quarter of fiscal 2008. The $2.2 million increase in medical supplies is a result of a 4.1% increase in open heart cases, a 32.1% increase in musculoskeletal cases and a 42.6% increase in the usage of drug eluting stents offset by a 20.6% decrease in the usage of bare metal stents. In addition, our average length of stay increased 9.3%, which resulted in a 11.3% increase in non-chargeable supply expense.

      Bad debt expense. Bad debt expense increased 22.6% to $12.5 million for the third quarter of fiscal 2009 from $10.2 million for the third quarter of fiscal 2008. As a percentage of net revenue, bad debt expense increased to 8.3% for the third quarter of fiscal 2009 as compared to 6.6% for the comparable period of fiscal 2008. Our total uncompensated care including charity care and bad debt expense was 9.5% of total net patient hospital revenue for the third quarter of fiscal 2009 compared to 9.6% of total net patient revenue for the third quarter of fiscal 2008. The total number of patients which applied and qualified for charity care reduced during third quarter of fiscal 2009 compared to the third quarter of fiscal 2008. We reported $3.2 million more charity deductions to net revenue during the third quarter of fiscal 2008 when compared to the third quarter of fiscal 2009.

      Other operating expenses. Other operating expenses increased 6.4% to $31.4 million for the third quarter of fiscal 2009 from $29.6 million for the third quarter of fiscal 2008. The increase is attributable to the following:

•

$1.1 million increase in professional fees associated with an internal assessment of certain controls and procedures completed during the quarter.

•

$0.8 million increase in penalty expense for the anticipated settlement of regulatory claims at two of our hospitals related to the identification, return and self-reporting of $0.7 million in reimbursement for certain procedures performed at those hospitals in prior fiscal years.

•

$0.4 million increase in severance payments.

The above increases were offset by a decrease in our medical malpractice insurance expense of $0.6 million for the third quarter of fiscal 2009 compared to the third quarter of fiscal 2008.

      Interest expense. Interest expense decreased $2.7 million or 70.2% to $1.2 million for the third quarter of fiscal 2009 from $3.9 million for the third quarter of fiscal 2008. The $2.7 million decrease in interest expense is primarily attributable to the overall reduction in our outstanding debt, interest rates on our outstanding debt, and the capitalization of interest on our capital expansion projects. Capitalized interest was $0.8 million for the third quarter of fiscal 2009 compared to $0.4 million for the third quarter of fiscal 2008.

      Interest and other income. Interest and other income decreased to $0.1 million for the third quarter of fiscal 2009 from $0.3 million for the third quarter of fiscal 2008. The decrease in interest and other income is a direct result of the approximately $77.9 million decrease in our cash and cash equivalent balance from June 30, 2008 to June 30, 2009, which resulted in a reduction in interest earned on cash balances.

      Minority interest share of earnings of consolidated subsidiaries. Minority interest share of earnings of consolidated subsidiaries decreased to $2.3 million for the first three months of fiscal 2009 from $3.9 million for the comparable period of fiscal 2008. We expect our earnings allocated to minority interests to fluctuate in future periods as we either recognize disproportionate losses and/or recoveries thereof through disproportionate profit recognition. For a more complete discussion of our accounting for minority interests, including the basis for disproportionate allocation accounting, see Critical Accounting Policies in our Annual Report on Form 10-K for the fiscal year ended September 30, 2008.

      Income tax expense. Income tax expense was $0.5 million for the third quarter of fiscal 2009 compared to $3.5 million for the third quarter of fiscal 2008, which represents an effective tax rate of approximately 47.8% and 41.4% for the respective periods. The 47.8% rate for the third quarter of fiscal 2009 is the effective rate created due to permanent, non-recurring items during the reporting period. The income tax rate for the third quarter of fiscal 2008 was negatively impacted by the write-off goodwill based on the valuation of one of our hospitals we subsequently sold. The write-off of goodwill is a non-deductible tax expense in the period the write-off occurs.

      (Loss) income from discontinued operations, net of taxes. (Loss) income from discontinued operations, net of taxes, reflects the results of Dayton Heart Hospital, Cape Cod Cardiology, and the Heart Hospital of Lafayette for the third quarter of fiscal 2009 and fiscal 2008. Income from discontinued operations decreased to a loss of $0.1 million, net of tax, for the third quarter of fiscal 2009 from income of $6.9 million, net of tax, for the comparable period of fiscal 2008. Loss from discontinued operations during the third quarter of fiscal 2009 related to continued payments of liabilities associated with the divested facilities, whereas the income from discontinued operations from same quarter of fiscal 2008 was related to operating income from Cape Cod Cardiology offset by losses at Dayton Heart Hospital.

Nine months ended June 30, 2009 Compared to Nine Months Ended June 30, 2008

      Statement of Operations Data . The following table presents our results of operations in dollars and as a percentage of net revenue for the periods indicated:

		Nine Months Ended June 30,
		(in thousands except percentages)
										Increase/Decrease								% of Net Revenue
		2009				2008				$				%				2009				2008
Net revenue		$	462,874			$	455,168			$	7,706				1.7	%			100.0	%			100.0	%
Operating expenses:
Personnel expense			153,644				150,060				3,584				2.4	%			33.2	%			33.0	%
Medical supplies expense			131,457				123,155				8,302				6.7	%			28.4	%			27.0	%
Bad debt expense			34,558				31,852				2,706				8.5	%			7.5	%			7.0	%
Other operating expenses			96,022				88,996				7,026				7.9	%			20.8	%			19.5	%
Pre-opening expenses			1,340				643				697				108.4	%			0.3	%			0.1	%
Depreciation			23,258				22,535				723				3.2	%			5.0	%			5.0	%
Amortization			589				411				178				43.3	%			0.1	%			0.1	%
Loss on disposal of property, equipment and other assets			138				391				(253	)			64.7	%			0.0	%			0.1	%
Income from operations			21,868				37,125				(15,257	)			(41.1	)%			4.7	%			8.2	%
Other income (expenses):
Interest expense			(5,339	)			(11,658	)			6,319				54.2	%			(1.1	)%			(2.6	)%
Loss on early extinguishment of debt			(6,702	)			—				(6,702	)			(100.0	)%			(1.4	)%			—
Interest and other income, net			218				1,930				(1,712	)			(88.7	)%			—				0.4	%
Equity in net earnings of unconsolidated affiliates			7,044				6,842				202				3.0	%			1.5	%			1.5	%
Income from continuing operations before minority interest, income taxes and discontinued operations			17,089				34,239				(17,150	)			(50.1	)%			3.7	%			7.5	%
Minority interest share of earnings of consolidated subsidiaries			(9,703	)			(12,644	)			2,941				23.3	%			(2.1	)%			(2.8	)%
Income from continuing operations before income taxes and discontinued operations			7,386				21,595				(14,209	)			(65.8	)%			1.6	%			4.7	%
Income tax expense			2,998				8,917				(5,919	)			(66.4	)%			0.7	%			1.9	%
Income from continuing operations			4,388				12,678				(8,290	)			(65.4	)%			0.9	%			2.8	%
Income from discontinued operations, net of taxes			3,936				7,843				(3,907	)			49.8	%			0.9	%			1.7	%
Net income		$	8,324			$	20,521				(12,197	)			(59.4	)%			1.8	%			4.5	%